Overview

Safety And Efficacy Of Spirinolactone Plus Hydroflumethiazide In The Treatment Of Filipino Patients With Hypertension

Status:
Withdrawn
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Aldazide 25 mg OD will be given to Filipino hypertensive patients, and there will be 2 follow-up visits on week 4 and week 8 to monitor for safety and efficacy as primary and secondary outcomes, respectively.
Details
Lead Sponsor:
Pfizer
Treatments:
Hydroflumethiazide